Log in to save to my catalogue

Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus i...

Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus i...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_c372aee3045841d7bf925f1ae98c8480

Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial

About this item

Full title

Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial

Publisher

England: BMJ Publishing Group Ltd

Journal title

Journal for immunotherapy of cancer, 2024-02, Vol.12 (2), p.e008189

Language

English

Formats

Publication information

Publisher

England: BMJ Publishing Group Ltd

More information

Scope and Contents

Contents

BackgroundIn CheckMate 9LA, nivolumab plus ipilimumab with chemotherapy prolonged overall survival (OS) versus chemotherapy regardless of tumor PD-L1 expression or histology. We report updated efficacy and safety in all randomized patients with a minimum 4-year follow-up and an exploratory treatment-switching adjustment analysis in all treated pati...

Alternative Titles

Full title

Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_c372aee3045841d7bf925f1ae98c8480

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_c372aee3045841d7bf925f1ae98c8480

Other Identifiers

ISSN

2051-1426

E-ISSN

2051-1426

DOI

10.1136/jitc-2023-008189

How to access this item